Andere Sprachen Recce Pharmaceuticals Ltd

Aktien

A2ADQM

AU000000RCE5

RCE

Verzögert Australian S.E. Andere Börsenplätze 07:19:28 06.05.2024			% 5 Tage	% 1. Jan.
0,65 ^AUD	+1,56 %		+2,36 %	+21,50 %

30.04.	Recce Pharmaceuticals Ltd. gibt bekannt, dass der Sicherheitsausschuss eine hohe Dosis von 4.000 mg in der Phase I/II-Studie mit RECCE® 327 zur Behandlung von Harnwegsinfektionen und Urosepsis genehmigt hat	CI
17.04.	Recce Pharmaceuticals Ltd. Fertigstellung von 5.000 RECCE 327 Dosen pro Woche unter Good Manufacturing Practice	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis	30.04.
Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis	30.04.
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)	17.04.
Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice	17.04.
Recce Pharmaceuticals Advances Production of Anti-Infective Medication	16.04.
Recce Pharmaceuticals Provides Business Update	10.04.
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024	10.04.
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives	04.04.
Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives	04.04.
Recce Pharmaceuticals Secures Israeli Patent for Anti-Infective Medication; Shares Rise 5%	03.04.
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio	22.03.
Recce Pharmaceuticals Secures Canadian Trademark for Antibiotic Medications	21.03.
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis	19.03.
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis	19.03.
Recce Pharmaceuticals Concludes Cohort Dosing in Synthetic Anti-Infectives Trial	15.03.
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis	14.03.
Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis	14.03.
Recce Makes Headway On Human Trials of Anti-Infective	13.03.
Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting	13.03.
Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance	12.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Recce Pharmaceuticals Ltd

Aktien

A2ADQM

AU000000RCE5

RCE

Andere Sprachen

Filter